Net income
-185 million USD
2025-07-01 – 2026-06-30
Fundies. English
BICARA THERAPEUTICS INC.
EDGAR13 filing records in this dataset, filed from 2024-08-22 to 2026-08-11. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 96.6 million USD Source
Exact value
96599000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 65.9 million shares Source
Exact value
65931128 shares
Reported share-count change
20.85% · 11.4 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-135 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -82948000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -53700000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -106834000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -82948000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -37508000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -81714000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -37508000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
400 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Capital expenditure: 42000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 0 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 280000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 42000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 60000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 120000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 60000 USD · 2026-01-01 – 2026-03-31 Source
Free cash flow
-135 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -82948000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -53700000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -106834000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -82948000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -37508000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -81714000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -37508000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 42000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 0 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 280000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 42000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 60000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 120000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 60000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-11.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2025-12-31
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 69.96 millionPrior period
−USD 68 million
–
Current period
−USD 137.95 million
–
Exact inputs and evidence
-137950000 − -67995000 = -69955000 USD
-67995000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-137950000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 32.08 millionPrior period
−USD 74.75 million
–
Current period
−USD 106.83 million
–
Exact inputs and evidence
-106834000 − -74751000 = -32083000 USD
-74751000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-106834000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+294.4%Prior period
USD 71,000
–
Current period
USD 280,000
–
Exact inputs and evidence
280000 − 71000 = 209000 USD
71000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source280000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 51.99 million Exact valueExact value: -51985000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 45.63 million Exact valueExact value: -45628000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 586,000 Exact valueExact value: 586000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 46.21 million Calculation and evidence-45628000 − 586000 USD Exact free cash flow: -46214000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 68 million Exact valueExact value: -67995000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 74.75 million Exact valueExact value: -74751000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 71,000 Exact valueExact value: 71000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 74.82 million Calculation and evidence-74751000 − 71000 USD Exact free cash flow: -74822000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 137.95 million Exact valueExact value: -137950000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 106.83 million Exact valueExact value: -106834000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 280,000 Exact valueExact value: 280000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 107.11 million Calculation and evidence-106834000 − 280000 USD Exact free cash flow: -107114000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
13 filings · 631 latest values · 631 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0002023658, 2023658, BCAX, edgar:2023658
Also known as BICARA THERAPEUTICS INC., Bicara Therapeutics Inc.